目的:慢性乙型肝炎(CHB)是乙型肝炎病毒(HBV)感染的严重后果,是一个世界性难题,数以百万计的病人期待着有效治疗方法。近年来拉米夫定(Iamivudine,3TC)研究课题,为抗HBV治疗开辟了新途径。方法:以近年发表的文献为基础,就3TC作用机制、临床应用情况、存在问题进行综述。结果与结论:3TC经5年临床研究证明,治疗CHB已初露曙光,但亟待解决问题很多,针对这些问题专家们提出临床应用指导意见。 Purpose: Chronic hepatitis B (CHB) is a grave consequence of hepatitis B virus (HBV) infection and is a worldwide problem that millions of patients are looking for effective treatments. In recent years, lamivudine (Iamivudine, 3TC) research topics, opened up a new way for anti-HBV treatment. Methods: Based on the literature published in recent years, the mechanism of 3TC, clinical application and existing problems were reviewed. RESULTS AND CONCLUSION: After 3TC clinical trial, 3TC proved that the treatment of CHB had its first dawn, but there were many problems to be solved urgently. The experts for these problems put forward clinical application guidelines.